Phase II study of methyl-glyoxal bis-guanylhydrazone (NSC 3296) in advanced ovarian cancer.
Thirty-nine patients received 600 mg/m2 OF MGBG intravenously every week for the treatment of advanced refractory ovarian cancer. Twenty-seven of these received adequate trials, and only two had partial remissions lasting 3 1/2 and 4 months each. Toxicity was substantial, with severe hematologic toxicity in 26%, diarrhea in 22% (severe in 7%), skin rash in 26% (severe in 7%), and vomiting in 70% (severe in 11%). Fatigue, facial paresthesias, and flushing during drug administration were frequent. It appears that MGBG in this dose and schedule has little activity against advanced ovarian cancer.
D001769:Blood / Q000187:drug effects; D004341:Drug Evaluation; D005221:Fatigue / Q000139:chemically induced; D005260:Female; D006146:Guanidines / Q000627:therapeutic use*; D006801:Humans; D008935:Mitoguazone / Q000009:adverse effects / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D014839:Vomiting / Q000139:chemically induced
D006146:Guanidines; D008935:Mitoguazone